Emergent Biosolutions INC Form 4 insider transactions

Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions, disposed of 464 shares of common stock on June 8, 2024, to cover tax obligations.

Coleen Glessner, an executive at Emergent BioSolutions, reported a transaction involving the withholding of common stock to cover tax obligations.

Richard S. Lindahl, EVP and Chief Financial Officer of Emergent BioSolutions Inc., reports a transaction involving the withholding of common stock to cover tax obligations.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, disposed of 1,167 shares of common stock on June 8, 2024, to cover tax obligations.

Director Kathryn C. Zoon sold 10,000 shares of Emergent BioSolutions Inc. (EBS) at $6.11 per share on June 4, 2024.

Director Kathryn C. Zoon sold 1,830 shares of Emergent BioSolutions Inc. (EBS) common stock at a price of $4.61 per share on May 29, 2024, according to a Form 4 filing with the SEC.

Director Keith Katkin receives stock options and restricted stock units (RSUs) from Emergent BioSolutions as part of annual compensation for board and committee service.

Director Neal Franklin Fowler reports receiving stock options and restricted stock units (RSUs) from Emergent BioSolutions as part of annual compensation for board service.

Director Donald W. DeGolyer receives stock and options grant from Emergent BioSolutions Inc. for board and committee service.

Director Marvin L. White reports acquisition of Emergent BioSolutions stock and stock options as part of annual compensation.

Director Sujata Tyagi Dayal reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc.

Director Louis W. Sullivan reports acquisition of Emergent BioSolutions stock and options as part of annual grants for board service.

Director Zsolt Harsanyi reports receiving stock options and restricted stock units from Emergent BioSolutions as part of their compensation for board and committee service.

Director Kathryn C. Zoon reports acquisition of stock options and restricted stock units in Emergent BioSolutions Inc.

Director Richard Ronald receives annual grant of restricted stock units and stock options for board service at Emergent BioSolutions.

Director Kathryn C. Zoon reports selling 1,089 shares of Emergent BioSolutions Inc. (EBS) at $5.78 per share on May 21, 2024, pursuant to a pre-arranged trading plan.

Coleen Glessner, EVP at Emergent BioSolutions, disposed of 585 shares of common stock on April 7, 2024, to cover tax obligations.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, disposed of 665 shares of common stock on April 7, 2024, to cover tax obligations.

Emergent BioSolutions CEO Joseph C. Papa was granted 750,000 stock options on March 13, 2024, according to a Form 4 filing with the SEC.

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions, acquired 125,000 employee stock options on March 13, 2024.

Coleen Glessner, EVP at Emergent BioSolutions, reports acquisition of employee stock options.

Jennifer Lynne Fox, EVP, Ext Aff, GC, Corp Sec of Emergent BioSolutions Inc., reports acquisition of 125,000 employee stock options.

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions, reports the acquisition of 125,000 employee stock options.

William Hartzel, SVP, Bioservices at Emergent BioSolutions, reports the acquisition of 125,000 employee stock options.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, disposed of 346 shares of common stock on March 5, 2024, to cover tax obligations.

Coleen Glessner, EVP at Emergent BioSolutions, reports disposition of shares to cover tax obligations.

Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions Inc., reports disposing of common stock to cover tax obligations arising from equity compensation.

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions, reported disposing of shares to cover tax obligations on February 29, 2024, and March 1, 2024.

EVP Jennifer Lynne Fox reports disposals of Emergent BioSolutions stock to cover tax obligations arising from equity compensation.

Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions Inc., reports the disposition of 105 shares of common stock to cover tax obligations on February 23, 2024.